David W Dick

Dr. David W Dick


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Epidemics
Verified
Journal Article
Open access
LCLauren Childs
Lauren Childs
DDDavid W Dick
David W Dick
ZFZhilan Feng
Zhilan Feng
JHJane Heffernan
Jane Heffernan
JLJing Li
Jing Li
GRGergely Röst
Gergely Röst
SARS-CoV-2, the causative agent of COVID-19, has caused devastating health and economic impacts around the globe since its appearance in late 2019. The advent of effective vaccines leads to open questions on how best to vaccinate the population. To address such questions, we developed a model of COVID-19 infection by age that includes the waning and boosting of immunity against SARS-CoV-2 in the context of infection and vaccination. The model also accounts for changes to infectivity of the virus, such as public health mitigation protocols over time, increases in the transmissibility of variants of concern, changes in compliance to mask wearing and social distancing, and changes in testing rates. The model is employed to study public health mitigation and vaccination of the COVID-19 epidemic in Canada, including different vaccination programs (rollout by age), and delays between doses in a two-dose vaccine. We find that the decision to delay the second dose of vaccine is appropriate in the Canadian context. We also find that the benefits of a COVID-19 vaccination program in terms of reductions in infections is increased if vaccination of 15–19 year olds are included in the vaccine rollout.

18 April 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CKChapin S. Korosec
Chapin S. Korosec
DDDavid W Dick
David W Dick
IMIain R. Moyles
Iain R. Moyles
JWJames Watmough
James Watmough
SARS-CoV-2 lipid nanoparticle mRNA vaccines continue to be administered as the predominant prophylactic measure to reduce COVID-19 disease pathogenesis. Quantifying the kinetics of the secondary immune response from subsequent doses beyond the primary series and understanding how dose-dependent immune waning kinetics vary as a function of age, sex, and various comorbidities remains an important question. We study anti-spike IgG waning kinetics in 152 individuals who received an mRNA-based primary series (first two doses) and a subset of 137 individuals who then received an mRNA-based booster dose. We find the booster dose elicits a 71–84% increase in the median Anti-S half life over that of the primary series. We find the Anti-S half life for both primary series and booster doses decreases with age. However, we stress that although chronological age continues to be a good proxy for vaccine-induced humoral waning, immunosenescence is likely not the mechanism, rather, more likely the mechanism is related to the presence of noncommunicable diseases, which also accumulate with age, that affect immune regulation. We are able to independently reproduce recent observations that those with pre-existing asthma exhibit a stronger primary series humoral response to vaccination than compared to those that do not, and further, we find this result is sustained for the booster dose. Finally, via a single-variate Kruskal-Wallis test we find no difference between male and female humoral decay kinetics, however, a multivariate approach utilizing Least Absolute Shrinkage and Selection Operator (LASSO) regression for feature selection reveals a statistically significant (p $$<1\times 10^{-3}$$ < 1 × 10 - 3 ), albeit small, bias in favour of longer-lasting humoral immunity amongst males.

8 December 2023 in Scientific Data
Verified
Journal Article
Open access
PDF file
AAAnna Akanteva
Anna Akanteva
DDDavid W Dick
David W Dick
SAShirin Amiraslani
Shirin Amiraslani
JHJane Heffernan
Jane Heffernan
The Covid-19 pandemic has prompted governments across the world to enforce a range of public health interventions. We introduce the Covid-19 Policy Response Canadian tracker (CPRCT) database that tracks and records implemented public health measures in every province and territory in Canada. The implementations are recorded on a four-level ordinal scale (0–3) for three domains, (Schools, Work, and Other), capturing differences in degree of response. The data-set allows the exploration of the effects of public health mitigation on the spread of Covid-19, as well as provides a near-real-time record in an accessible format that is useful for a diverse range of modeling and research questions.

23 December 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
DDDavid W Dick
David W Dick
LCLauren Childs
Lauren Childs
ZFZhilan Feng
Zhilan Feng
JLJing Li
Jing Li
GRGergely Röst
Gergely Röst
JHJane Heffernan
Jane Heffernan
COVID-19 seroprevalence changes over time, with infection, vaccination, and waning immunity. Seroprevalence estimates are needed to determine when increased COVID-19 vaccination coverage is needed, and when booster doses should be considered, to reduce the spread and disease severity of COVID-19 infection. We use an age-structured model including infection, vaccination and waning immunity to estimate the distribution of immunity to COVID-19 in the Canadian population. This is the first mathematical model to do so. We estimate that 60–80% of the Canadian population has some immunity to COVID-19 by late Summer 2021, depending on specific characteristics of the vaccine and the waning rate of immunity. Models results indicate that increased vaccination uptake in age groups 12–29, and booster doses in age group 50+ are needed to reduce the severity COVID-19 Fall 2021 resurgence.

7 March 2023 in Journal of Theoretical Biology
Verified
Journal Article
Closed access
CKChapin S. Korosec
Chapin S. Korosec
MBMatthew Betti
Matthew Betti
DDDavid W Dick
David W Dick
HOHsu Kiang Ooi
Hsu Kiang Ooi
IMIain Moyles
Iain Moyles
JHJane Heffernan
Jane Heffernan

9 October 2021 in COVID
Verified
Journal Article
Open access
PDF file
CVCarole Vignals
Carole Vignals
DDDavid W Dick
David W Dick
RTRodolphe Thiébaut
Rodolphe Thiébaut
LWLinda Wittkop
Linda Wittkop
MPMélanie Prague
Mélanie Prague
JHJane Heffernan
Jane Heffernan
Non-pharmaceutical interventions have been implemented intermittently for more than a year in most countries of the world to mitigate the COVID-19 epidemic. In France, while the vaccination campaign is progressing, the French government has decided to remove many public health restrictions such as business closure, lockdowns, and curfews. Nonetheless, social distancing, mask wearing, and hand washing (also called barrier gestures) are still recommended. We utilize an age-structured compartmental SEIR model that takes into account the SARS-CoV-2 waning immunity, vaccination, and increased transmissibility from variants of concern to estimate if barrier gestures can be relaxed without causing a resurgence of severe infections. This model assumes that the susceptibility to infection is a function of immunity status, which depends on initial infection severity and vaccination status. It is calibrated on confirmed COVID-19 cases from the French surveillance database, and accounts for changes in contact behaviors due to the implementation of nation-wide public health policies. We study the partial and full relaxation of barrier gestures occurring from August to December 2021 under various immunity duration assumptions. Maintaining the application of barrier gestures appears essential to avoid a resurgence of severe infections that would exceed French health care capacities, while surmounting vaccine hesitancy represents the key to consider their relaxation. Immunity duration assumptions significantly influence the short-term dynamic of the epidemic, which should be considered for further modelling.